Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Pathologic heterogeneity persists in early active multiple sclerosis lesions
Metz, Imke , Weigand, Stephen D. , Popescu, Bogdan , Frischer, Josa M. , Parisi, Joseph E. , Guo, Yong , Lassmann, Hans , Brück, Wolfgang , Lucchinetti, Claudia F. , Guo, Yong

Annals of Neurology | April 26, 2014 | Volume: 75 | Issue: 5 | Pages: 728-738

10.1002/ana.24163 | PMID 24771535 Get It

Objective Multiple sclerosis (MS) lesions demonstrate immunopathological heterogeneity in patterns of demyelination. Previous cross‐sectional studies reported immunopatterns of demyelination were identical among multiple active demyelinating lesions from the same individual, but differed between individuals, leading to the hypothesis of intraindividual pathological homogeneity and interindividual heterogeneity. Other groups suggested a time‐dependent heterogeneity of lesions. The objective of our present study was to analyze tissue samples collected longitudinally to determine whether patterns of demyelination persist over time within a given patient. Methods Archival tissue samples derived from patients with pathologically confirmed central nervous system inflammatory demyelinating disease who had undergone either diagnostic serial biopsy or biopsy followed by autopsy were analyzed immunohistochemically. The inclusion criteria consisted of the presence of early active demyelinating lesions—required for immunopattern classification—obtained from the same patient at 2 or more time points. Results Among 1,321 surgical biopsies consistent with MS, 22 cases met the study inclusion criteria. Twenty‐one patients (95%) showed a persistence of immunopathological patterns in tissue sampled from different time points. This persistence was demonstrated for all major patterns of demyelination. A single patient showed features suggestive of both pattern II and pattern III on biopsy, but only pattern II among all active lesions examined at autopsy. Interpretation These findings continue to support the concept of patient‐dependent immunopathological heterogeneity in early MS and suggest that the mechanisms and targets of tissue injury may differ among patient subgroups. These observations have potentially significant implications for individualized therapeutic approaches. Ann Neurol 2014;75:728–738
A new type of reconstruction of the hemipelvis after Type 3 amputative sacrectomy using pedicled fibula
Starantzis, Konstantinos A., Sakellariou, Vasileios I. , Rose, Peter S. , Yaszemski, Michael J. , Papagelopoulos, Panayiotis J.

Journal of Neurosurgery: Spine | April 25, 2014 | Volume: 21 | Issue: 2 | Pages: 195-202

10.3171/2014.1.spine13245 | PMID 24766289 Get It

This is a technical note of pelvic reconstruction performed by an advanced multidisciplinary team. The authors report a new 3-stage reconstruction of the hemipelvis after Type 3 sacrectomy involving instrumented spinoiliac arthrodesis and pedicled fibula grafting in 2 patients. The anterior stage of the procedure begins with a transabdominal approach to mobilize the viscera and to free up the tumor from the vessels. The posterior divisions of internal iliac vessels, the middle sacral vessels, and the lateral sacral vessels are then ligated. An anterior vertebrectomy is done at the appropriate level, followed by an anterior osteotomy through the lateral planed surgical margin of the sacrum close to the salvaged sacroiliac joint. The second stage includes a major sacral resection with lower-extremity amputation from the pubic symphysis through the intact side of the sacrum, ipsilateral pedicled fibula harvesting, and closure with an ipsilateral pedicled quadriceps flap. The final stage involves reconstruction with lumboiliac instrumentation. The pedicled fibular graft left from the second stage is then placed distally within the previously created iliopectineal docking site and proximally within the L-5 docking site. The authors believe that this is a feasible and reproducible technique with theoretical advantages that have to be proved in the long-term follow-up.
Osteoporosis Prevention, Screening, and Treatment: A Review
Kling, Juliana M. , Sandhu, Nicole P. , Clarke, B.L. , Kling, Juliana M

Journal of Women's Health | April 25, 2014 | Volume: 23 | Issue: 7 | Pages: 563-572

10.1089/jwh.2013.4611 | PMID 24766381 Get It

Osteoporosis, defined as low bone mass leading to increased fracture risk, is a major health problem that affects approximately 10 million Americans. The aging U.S. population is predicted to contribute to as much as a 50% increase in prevalence by 2025. Although common, osteoporosis can be clinically silent, and without prevention and screening, the costs of osteoporotic fracture–related morbidity and mortality will burden the U.S. healthcare system. This is a particularly relevant concern in the context of diminishing health care resources. Dual-energy X-ray absorptiometry is the most widely used, validated technique for measuring bone mineral density (BMD) and diagnosing osteoporosis. Cost-effectiveness analyses support early detection and treatment of high-risk patients with antiresorptive medications such as bisphosphonates. Moreover, optimization of bone health throughout life can help prevent osteoporosis. Current guidelines recommend screening women by age 65 years, but because no guidelines for screening intervals exist, decisions are made on the basis of clinical judgment alone. Although the recent literature provides some guidance, this review further explores current recommendations in light of newer evidence to provide more clarity on prevention, screening, and management strategies for patients with osteoporosis in the primary care setting.
RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study
Camilleri, Michael , Carlson, Paula, Busciglio, Irene, Nair, Asha, Gibbons, Simon J. , Farrugia, Gianrico , Klee, Eric W. , Nair, Asha A, Acosta, Andrés , Gibbons, S J

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 25, 2014 | Volume: 306 | Issue: 12 | Pages: G1089-G1098

10.1152/ajpgi.00068.2014 | PMID 24763552 Get It

Our aim was to conduct a pilot case-control study of RNA expression profile using RNA sequencing of rectosigmoid mucosa of nine females with -diarrhea-predominant irritable bowel syndrome (IBS-D) with accelerated colonic transit and nine female healthy controls. Mucosal total RNA was isolated and purified, and next-generation pair-end sequencing was performed using Illumina TruSeq. Analysis was carried out using a targeted approach toward 12 genes previously associated with IBS and a hypothesis-generating approach. Of the 12 targeted genes tested, patients with IBS-D had decreased mRNA expression of TNFSF15 (fold change controls to IBS-D: 1.53, P = 0.01). Overall, up- and downregulated mRNA expressions of 21 genes ( P = 10−5 to 10−8; P values with false detection rates are shown) were potentially relevant to IBS-D including the following: neurotransmitters [ P2RY4 ( P = 0.001), vasoactive intestinal peptide ( VIP, P = 0.02)]; cytokines [ CCL20 ( P = 0.019)]; immune function [ C4BPA complement cascade ( P = 0.0187)]; interferon-related [ IFIT3 ( P = 0.016)]; mucosal repair and cell adhesion [trefoil protein ( TFF1, P = 0.012)], retinol binding protein [ RBP2 ( P = 0.017)]; fibronectin ( FN1, P = 0.009); and ion channel functions [guanylate cyclase ( GUCA2B, P = 0.017), PDZ domain-containing protein 3 ( PDZD3, P = 0.029)]. Ten genes associated with functions related to pathobiology of IBS-D were validated by RT-PCR. There was significant correlation in fold changes of the selected genes ( Rs = 0.73, P = 0.013). Up- or downregulation of P2RY4, GUC2AB, RBP2, FNI, and C4BPA genes were confirmed on RT-PCR, which also revealed upregulation of farnesoid X receptor ( FXR) and apical sodium-coupled bile acid transporter ( IBAT/ASBT). RNA-Seq and RT-PCR analysis of rectosigmoid mucosa in IBS-D show transcriptome changes that provide the rationale for validation studies to explore the role of mucosal factors in the pathobiology of IBS-D.
Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth
Wang, Dingzhi , Fu, Lingchen, Guo, Lixia , Chaturvedi, Rupesh , Wilson, Keith T. , Wei, Ning , Sun, Xiaofei , Dey, Sudhansu K. , DuBois, Raymond N.

Proceedings of the National Academy of Sciences | April 25, 2014 | Volume: 111 | Issue: 19 | Pages: 7084-7089

10.1073/pnas.1324233111 | PMID 24763687 Get It

Significance Our study not only reveals a novel role of peroxisome proliferator-activated receptor δ (PPARδ) in colonic inflammation and colitis-associated tumorigenesis, but also provides some rationale for development of PPARδ antagonists as new therapeutic agents in the treatment of inflammatory bowel disease and colitis-associated colorectal cancer. Moreover, our findings indicate that prostaglandin E 2 generated by chronic inflammation is a crucial mediator connecting chronic inflammation and colorectal carcinogenesis.
Evidence that the Lung Adenocarcinoma EML4-ALK Fusion Gene Is not Caused by Exposure to Secondhand Tobacco Smoke During Childhood
Wang, Yi , Jen, Jin , Yi, Eunhee S. , Olivo‐Marston, Susan , Harris, Curtis C. , Ryan, Bríd M. , Yang, Ping

Cancer Epidemiology, Biomarkers & Prevention | April 24, 2014 | Volume: 23 | Issue: 7 | Pages: 1432-1434

10.1158/1055-9965.epi-14-0224 | PMID 24755712 Get It

Abstract Background: The EML4-ALK fusion gene is more frequently found in younger, never smoking patients with lung cancer. Meanwhile, never smokers exposed to secondhand tobacco smoke (SHS) during childhood are diagnosed at a younger age compared with never smoking patients with lung cancer who are not exposed. We, therefore, hypothesized that SHS, which can induce DNA damage, is associated with the EML4-ALK fusion gene. Methods: We compared the frequency of the EML4-ALK fusion gene among 197 never smoker patients with lung cancer with and without a history of exposure to SHS during childhood at Mayo Clinic. Results: The EML4-ALK fusion gene was detected in 33% of cases from never smokers with a history of SHS exposure during childhood, whereas 47% of never smoking lung cancer cases without a history of childhood SHS exposure tested positive for the fusion gene. Conclusions: The EML4-ALK fusion gene is not enriched in tumors from individuals exposed to SHS during childhood. Impact: These data suggest that childhood exposure to SHS is not a significant etiologic cause of the EML4-ALK fusion gene in lung cancer. Cancer Epidemiol Biomarkers Prev; 23(7); 1432–4. ©2014 AACR.
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
Knutson, Keith L. , Stone, Brad, Reiman, Jennifer M. , Behrens, Marshall D., Prosperi, Christine , Gad, Ekram, Smorlesi, Arianna, Knutson, Keith L. , Lu, Hailing , Disis, Mary Lenora

The Journal of Immunology | April 24, 2014 | Volume: 177 | Issue: 3 | Pages: 1526-1533

10.4049/jimmunol.177.3.1526 | PMID 16849459 Get It

Abstract Tumors evade both natural and pharmacologically induced (e.g., vaccines) immunity by a variety of mechanisms, including induction of tolerance and immunoediting. Immunoediting results in reshaping the immunogenicity of the tumor, which can be accompanied by loss of Ag expression and MHC molecules. In this study, we evaluated immunoediting in the neu-transgenic mouse model of breast cancer. A tumor cell line that retained expression of rat neu was generated from a spontaneous tumor of the neu-transgenic mouse and, when injected into the non-transgenic parental FVB/N mouse, resulted in the development of a strong immune response, initial rejection, and ultimately the emergence of neu Ag-loss variants. Morphologic and microarray data revealed that the immunoedited tumor cells underwent epithelial to mesenchymal transition accompanied by an up-regulation of invasion factors and increased invasiveness characteristic of mesenchymal tumor cells. These results suggest that immunoediting of tumor results in cellular reprogramming may be accompanied by alterations in tumor characteristics including increased invasive potential. Understanding the mechanisms by which tumors are immunoedited will likely lead to a better understanding of how tumors evade immune detection.
Catheter Ablation Related Mitral Valve Injury: The Importance of Early Recognition and Rescue Mitral Valve Repair
Hu, Tiffany , Ebrille, Elisa , Syed, Faisal F. , Vaidya, Vaibhav R. , Cha, Yong‐Mei , Valverde, Arturo M. , Friedman, Paul A. , Suri, Rakesh M. , Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | April 24, 2014 | Volume: 25 | Issue: 9 | Pages: 971-975

10.1111/jce.12439 | PMID 24758402 Get It

Mitral Valve Injury with Catheter AblationIntroductionAn increasing number of catheter ablations involve the mitral annular region and valve apparatus, increasing the risk of catheter interaction with the mitral valve (MV) complex. We review our experience with catheter ablation‐related MV injury resulting in severe mitral regurgitation (MR) to delineate mechanisms of injury and outcomes.MethodsWe searched the Mayo Clinic MV surgical database over a 19‐year period (1993–2012) and the electrophysiologic procedures database over a 23‐year period (1990–2013) and identified 9 patients with catheter ablation related MV injury requiring clinical intervention.ResultsIndications for ablation included atrial fibrillation (AF) [n = 4], ventricular tachycardia (VT) [n = 3], and left‐sided accessory pathways [n = 2]. In all 4 AF patients, a circular mapping catheter entrapped in the MV apparatus was responsible for severe MR. In all 3 VT patients, radiofrequency energy delivery led to direct injury to the MV apparatus. In the 2 patients with accessory pathways, both mechanisms were involved (1 per patient). Six patients required surgical intervention (5 MV repair, 1 catheter removal). One patient developed severe functional MR upon successful endovascular catheter disentanglement that improved spontaneously. Two VT patients with persistent severe postablation MR were managed nonsurgically, 1 of whom died 3 months postprocedure.ConclusionCircular mapping catheter entrapment and ablation at the mitral annulus are the most common etiologies of MV injury during catheter ablation. Close surveillance of the MV is needed during such procedures and early surgical repair is important for successful salvage if significant injury occurs.
Compatibility of Electroanatomical Mapping Systems with a Concurrent Percutaneous Axial Flow Ventricular Assist Device
Vaidya, Vaibhav R. , Madhavan, Malini , Noheria, Amit , Shahid, Mohammed , Walters, Jacob, Ladewig, Dorothy J., Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | April 24, 2014 | Volume: 25 | Issue: 7 | Pages: 781-786

10.1111/jce.12437 | PMID 24758340 Get It

Electromagnetic Interference with Ventricular Assist DeviceBackgroundHemodynamic instability hinders activation and entrainment mapping during ventricular tachycardia ablation. The Impella 2.5 microaxial flow device (MFD; Abiomed Inc., Danvers, MA, USA) is used to prevent hemodynamic instability during electrophysiologic study. However, electromagnetic interference (EMI) generated by this device can preclude accurate electroanatomic mapping.MethodsImpella was placed in the left ventricle of 7 canines for circulatory support. Electroanatomic mapping during sinus rhythm, ventricular pacing, and ventricular fibrillation (VF) was performed using magnet‐ (CARTO3, Biosense Webster Inc., Diamond Bar, CA, USA) and impedance‐ (EnSite Velocity System/EnSite NavX, St. Jude Medical Inc., St. Paul, MN, USA) based systems. Distance from device to points with severe EMI precluding acquisition was compared to points with mild/no EMI. Two methods were used to reduce EMI: (1) titration of MFD performance, and (2) impedance‐only mapping combined with manual annotation of activation.ResultsSevere EMI did not occur during impedance‐based mapping. Severe EMI was observed using CARTO3 at 9.4% of all points attempted at maximum performance level (P8) of device. Severe EMI occurred at points closer to device (40.1 ± 16.8 mm) versus (55.5 ± 20.0 mm) for mild/no EMI, P < 0.0001. Severe EMI using CARTO3 was resolved by either (1) reduction of performance from P8 to P6 or (2) impedance‐only mapping with manual annotation.ConclusionConcurrent use of MFD caused EMI to prevent acquisition of points with magnet‐based mapping. Predictors for EMI were distance from device and performance level. Temporary reductions to P6 or impedance‐only mapping are 2 methods to resolve EMI.